Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 89 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Janux Therapeutics Inc | JANX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 48.85 | 08:29:51 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 48.85 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 6 | 89 | - | 5.65 - 58.6936 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:41:43 | 1 | $ 48.20 | USD |
Janux Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.52B | 51.66M | - | 8.08M | -58.29M | -1.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Janux Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JANX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 49.94 | 54.76 | 47.28 | 51.11 | 822,832 | -1.09 | -2.18% |
| 1 Month | 40.00 | 56.27 | 34.63 | 45.38 | 764,896 | 8.85 | 22.13% |
| 3 Months | 9.77 | 58.6936 | 7.79 | 43.69 | 947,571 | 39.08 | 400.00% |
| 6 Months | 7.35 | 58.6936 | 5.65 | 39.25 | 503,464 | 41.50 | 564.63% |
| 1 Year | 15.17 | 58.6936 | 5.65 | 34.23 | 306,201 | 33.68 | 222.02% |
| 3 Years | 34.00 | 58.6936 | 5.65 | 28.38 | 182,830 | 14.85 | 43.68% |
| 5 Years | 34.00 | 58.6936 | 5.65 | 28.38 | 182,830 | 14.85 | 43.68% |
Janux Therapeutics Description
| Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. |
